Alzheimer's disease risk factors as related to cerebral blood flow: Additional evidence

Medical Hypotheses

Volumn 50, Issue 1, 1998, Pages 25-36

  Crawford, J G ^a  

^a Indiana University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL ABUSE; ALZHEIMER DISEASE; BRAIN BLOOD FLOW; DEPRESSION; DOWN SYNDROME; GLUCOSE METABOLISM; HEAD INJURY; HUMAN; HYPOTHESIS; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SENESCENCE; SLEEP DISORDER;

EID: 0031963512     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(98)90173-6     Document Type: Article

References (133)

1. Crawford J G. Alzheimer's disease risk factors as related to cerebral blood flow. Med Hypotheses 1996; 46(4): 367-377.
2. Rao V S, van Duijn C M, Connor-Lacke L, Cupples L A, Growdon J H, Farrer L A. Multiple etiologies for Alzheimer disease are revealed by segregation analysis. Am J Hum Genet 1994; 55(5): 991-1000.
3. Haxby J V, Grady C L, Koss E et al. Heterogeneous anterior-posterior metabolic patterns in dementia of the Alzheimer's type. Neurology 1988; 38: 1853-1863.
4. McGeer P L, Kamo H, Harrop R et al. Positron emission tomography in patients with clinically diagnosed Alzheimer's disease. Can Med Assoc J 1986; 134(6): 597-607.
5. Eberling J L, Jagust W J, Reed B R, Baker M G. Reduced temporal lobe blood flow in Alzheimer's disease. Neurobiol Aging 1992; 13(4): 483-491.
6. O'brien J T, Eagger S, Syed G M, Sahakian B J, Levy R. A study of regional cerebral blood flow and cognitive performance in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1992; 55(12): 1182-1187.
7. Jobst K A, Smith A D, Barker C S et al. Association of atrophy of the medial temporal lobe with reduced blood flow in the posterior parietotemporal cortex in patients with a clinical and pathological diagnosis of Alzheimer's disease. J Neurol Neurosurg Psychiatry 1992; 55(3): 190-194.
8. DeKosky S T, Shih W J, Schmitt FA, Coupal J, Kirkpatrick C. Assessing utility of single photon emission computed tomography (SPECT) scan in Alzheimer disease. Alzheimer Dis Assoc Disord 1990; 4(1): 14-23.
9. Pearlson G D, Harris G J, Powers R E et al. Quantitative changes in mesial temporal volume, regional cerebral blood flow, and cognition in Alzheimer's disease. Arch Gen Psychiatry 1992; 49(5): 402-408.
10. Wyper D, Teasdale E, Patterson J et al. Abnormalities in rCBF and computed tomography in patients with Alzheimer's disease and in controls. Br J Radiol 1993; 66(781): 23-27.
11. Leenders K L, Perani D, Lammertsma A A et al. Cerebral blood flow, blood volume and oxygen utilization: normal values and effect of age. Brain 1990; 113: 27-47.
12. Pantano P, Baron J C, Lebrun-Grandie P, Duquesnoy N, Bousser M G, Comar D. Regional cerebral blood flow and oxygen consumption in human aging. Stroke 1984; 15: 635-641.
13. Meyer J S, Ishihara N, Deshmukh V D et al. Improved method for noninvasive measurement of regional cerebral blood flow by 133 Xenon inhalation, Part I: Description of method and normal values obtained in healthy volunteers. Stroke 1978; 9(3): 195-205.
14. Lenzi G L, Frackowiak R S, Jones T et al. CMRO2 and CBF by the oxygen-15 inhalation technique: results in normal volunteers and cerebrovascular patients. Eur Neurol 1981; 20(3): 285-290.
15. Pantano P, Baron J C, Lebrun-Grandie P, Duquesnoy N, Bousser M G, Comar D. Effects of normal aging on regional CBF and CMRO2 in humans. Monogr Neural Sci 1984; 11: 123-130.
16. Globus M, Cooper G, Melamed E. Reduction in regional cerebral blood flow during normal aging is not limited to elderly subjects. Monogr Neural Sci 1984; 11: 139-143.
17. Obrist W D. Cerebral blood flow and EEG changes associated with aging and dementia. In: Busse E W, Blazer D G, eds. Handbook of geriatric psychiatry. New York: Van Nostrand Reinhold, 1980: 83-101.
18. Kitamura S, Terashi A. Measurement of cerebral blood flow and metabolism in patients with Alzheimer's disease. Rinsho Byori 1990; 38(5): 494-498.
19. Hoyer S, Nitsch R, Oesterreich K. Predominant abnormality in cerebral glucose utilization in late-onset dementia of the Alzheimer type: a cross-sectional comparison against advanced late-onset and incipient early-onset cases. J Neural Transm Park Dis Dement Sect 1991; 3(1): 1-14.
20. Hanyu H, Abe S, Arai H. Diagnostic accuracy of single photon emission CT in Alzheimer-type dementia. Nippon Ronen Igakkai Zasshi 1992; 29(6): 463-468.
21. Jorm AF. The epidemiology of Alzheimer's disease and related disorders. London: Chapman and Hall, 1990: 147-150.
22. Markesbery W R, Ehmann W D. Brain trace elements in alzheimer disease. In: Terry R D, Katzman R, Bick K L, eds. Alzheimer Disease. New York: Raven, 1994: 353-367.
23. Martyn C N, Barker D J, Osmond C, Harris E C, Edwardson J A, Lacey R F. Geographical relation between Alzheimer's disease and aluminum in drinking water. Lancet 1989; i(8629): 59-62.
24. Martyn C N. The epidemiology of Alzheimer's disease in relation to aluminum. Ciba Found Symp 1992; 169: 69-79; discussion 79-86.
25. McLachlan D R, Fraser P E, Dalton A J. Aluminum and the pathogenesis of Alzheimer's disease: a summary of evidence. Ciba Found Symp 1992; 169: 87-98; discussion 99-108.
26. Perl D P, Good P F. Aluminum, Alzheimer's disease, and the olfactory system. Ann NY Acad Sci 1991; 640: 8-13.
27. Shigematsu K, McGeer P L. Accumulation of amyloid precursor protein in damaged neuronal processes and microglia following intracerebral administration of aluminum salts. Brain Res 1992; 593(1): 117-123.
28. Bjorkstein J, Yaeger L L, Wallace T. Control of Aluminum ingestion and its relation to longevity. Int J Vitam Nutr Res 1988; 58[4]: 462-465.
29. Mantyh P W, Ghilardi J R, Rogers S et al. Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of beta amyloid peptide. J Neurochem 1993; 61(3): 1171-1174.
30. Domingo J L, Gomez M, Sanchez D J, Llobet J M, Corbella J. Effect of various dietary constituents on gastrointestinal absorption of aluminum from drinking water and diet. Res Commun Chem Pathol Pharmacol 1993; 79(3): 377-380.
31. Duggan J M, Dickeson J E, Tynan P F, Houghton A, Flynn JE. Aluminum beverage cans as a dietary source of aluminum. Med J Aust 1992; 156(9): 604-605.
32. Basun H, Forssell L G, Wetterberg L, Winblad B. Metals and trace elements in plasma and cerebrospinal fluid in normal aging and Alzheimer's disease. J Neural Transm Park Dis Dement Sect 1991; 3(4): 231-258.
33. Corrigan F M, Van Rhijn A G, Ijomah G. Tin and fatty acids in dementia. Prostaglandins Leukot Essent Fatty Acids 1991; 43(4): 229-238.
34. Evans PH, Klinowski J, Yano E. Cephaloconiosis: a free radical perspective on the proposed particulate-induced etiopathogenesis of Alzheimer's dementia and related disorders. Med Hypotheses 1991; 34(3): 209-219.
35. Fratiglioni L, Ahlbom A, Viitanen M, Winblad B. Risk factors for late-onset Alzheimer's disease: a population-based case-control study. Ann Neurol 1993; 33(3): 258-266.
36. Simonsen L, Johnsen H, Lund S P, Matikainen E, Midtgard U, Wennberg A. Methodological approach to the evaluation of neurotoxicity data and the classification of neurotoxic chemicals. Scand J Work Environ Health 1994; 20(1): 1-12.
37. Erasmus R T, Savory J, Wills M R, Herman M M. Aluminum neurotoxicity in experimental animals. Ther Drug Monit 1993; 15(6): 588-592.
38. Oteiza P I, Keen C L, Han B, Golub MS. Aluminum accumulation and neurotoxicity in Swiss-Webster mice after long-term dietary exposure to aluminum and citrate. Metabolism 1993; 42(10): 1296-1300.
39. Bolla K I, Briefel G, Spector D, et al. Neurocognitive effects of aluminum. Arch Neurol 1992; 49(10): 1021-1026.
40. Nielsen A O, Kaaber K, Veien N K. Aluminum allergy caused by DPT vaccine. Ugeskr Laeger 1992; 154[27]: 1900-1901.
41. Armstrong R A, Winsper S J, Blair J A. Hypothesis: is Alzheimer's disease a metal-induced immune disorder? Neurodegeneration 1995; 4(1): 107-111.
42. Pericak-Vance M A, Bebout J L, Gaskell P C Jr. Linkage studies in familial Alzheimer's disease: evidence for chromosome 19 linkage. Am J Hum Genet 1991; 48(6): 1034-1050.
43. Strittmatter W J, Saunders A M, Schmechel D. Apolipoprotein E: high avidity binding to beta amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993; 90(5): 1977-1981.
44. Saunders A M, Strittmatter W J, Schmechel D et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993; 43(8): 1467-1472.
45. Henderson A S, Easteal S, Jorm A F. Apolipoprotein E allele epsilon 4, dementia, and cognitive decline in a population sample. Lancet 1995; 346(8987): 1387-1390.
46. Farrer LA, Cupples L A, van Duijn C M et al. Rate of progression of Alzheimer's disease is associated with genetic risk. Ann Neurol 1995; 38(5): 797-808.
47. Small G W, Mazziotta J C, Collins M T et al. Apolipoprotien E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. J Am Med Assoc 1995; 273(12): 942-947.
48. Reiman E M, Caselli R J, Yun L S et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E [see comments]. N Engl J Med 1996; 334(12): 752-758.
49. Michael C M, Kantor H I, Shore H. Further psychometric evaluation of older women - the effect of estrogen administration. J Gerontol 1970; 25: 337-341.
50. Furuhjelm M, Fedor-Freybergh P. The influence of estrogens on the psyche in climacteric and post-menopausal women. In: Van Keep P A, Greenblatt R B, Albeaux-Fernet M M, eds. Consensus on menopausal research. Baltimore: University Park Press, 1976: 84-93.
51. Hackman B W, Galbraith D. Replacement therapy with piperazine oestrone sulphate ('Harmogen') and its effect on memory. Curr Med Res Opin 1976; 4: 303-306.
52. Barrett-Connor E, Kritz-Silverstein D. Estrogen replacement therapy and cognitive function in older women. J Am Med Assoc 1993; 269(20): 2637-2641.
53. Fillit H, Weinreb H, Cholst I et al. Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. Psychoneuroendocrinology 1986; 11(3): 337-345.
54. Broe G A, Henderson A S, Creasey H. A case control study of Alzheimer's disease in Australia. Neurology 1990; 40(11): 1698-1707.
55. Graves A B, White E, Koepsell T et al. A case-control study of Alzheimer's disease. Ann Neurol 1990; 28(6): 766-774.
56. Heyman A, Wilkinson W E, Stafford J A, Helms M J, Sigmon A H, Weinberg T. Alzheimer's disease: a study of epidemiological aspects. Ann Neurol 1984; 15(4): 335-341.
57. Amaducci L A, Fratiglioni L, Rocca W A et al. Risk factors for clinically diagnosed Alzheimer's disease: a case-control study of an Italian population. Neurology 1986; 36(7): 922-931.
58. Paganini-Hill A, Henderson V W. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol 1994; 140: 256-261.
59. Henderson V W, Paganini-Hill A, Emanuel C K, Dünn M E, Buckwalter J G. Estrogen replacement therapy in older women: comparisons between Alzheimer's disease cases and non-demented control subjects. Arch Neurol 1994; 51(9): 896-900.
60. Ohkura T, Isse K, Akazawa K, Hamamoto M, Yaoi Y, Hagino N. Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer type: 7 case reports. Dementia 1995; 6(2): 99-107.
61. Shamma F N, Fayad P, Brass L, Sarrel P. Middle cerebral artery blood velocity during controlled ovarian hyper stimulation. Fertil Steril 1992; 57: 1022-1025.
62. St. George-Hyslop P H, Tanzi R E, Polinsky R J et al. The genetic defect causing Alzheimer's disease maps on chromosome 21. Science 1987; 235(4791): 885-890.
63. Sherrington R, Rogaev E I, Liang Y et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease [see comments]. Nature 1995; 375(6534): 754-760.
64. Levy-Lahad E, Wijsman E M, Nemens E, et al. A familial Alzheimer's disease locus on chromosome 1 [see comments]. Science 1995; 269(5226): 970-973.
65. van Duijn C M, Hofman A. Risk factors for Alzheimer's disease: the EURODEM collaborative re-analysis of case-control studies. Neuroepidemiology 1992; 11(suppl. 1): 106-113.
66. Bird T. Clinical genetics of familial Alzheimer disease. In: Terry R D, Katzman R, Bick K L, eds. Alzheimer Disease. New York: Raven, 1994: 65-74.
67. St George-Hyslop P H. The molecular genetics of Alzheimer disease. In: Terry R D, Katzman R, Bick K L, eds. Alzheimer Disease. New York: Raven, 1994: 345-352.
68. Roy C S, Sherrington C S. On the regulation of the blood supply of the brain. J Physiol 1890; 11: 85-108.
69. Kennedy A M, Frackowiak R S, Newman S K. Deficits in cerebral blood flow glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neurosci Lett 1995; 186(1): 17-20.
70. Kennedy A M, Rossor M N, Frackowiak R S. Positron emission tomography in familial Alzheimer's disease. Alzheimer Dis Assoc Disord 1995; 9(1): 17-20.
71. Katzman R. Education and the prevalence of dementia and Alzheimer's disease. Neurology 1993; 43(1): 13-20.
72. Stern Y, Gurland B, Tatemichi T K, Tang M X, Wilder D, Mayeux R. Influence of education and occupation on the incidence of Alzheimer's disease. J Am Med Assoc 1994; 271(13): 1004-1010.
73. Mortimer J A, Graves A B. Education and other socio-economic determinants of dementia and Alzheimer's disease. Neurology 1993; 43(suppl. 4): S39-S44.
74. Decety J, Sjoholm H, Ryding E, Stenberg G, Ingvar D H. The cerebellum participates in mental activity: tomographic measurements of regional cerebral blood flow. Brain Res 1990; 535(2): 313-317.
75. Ogawa S, Tank D W, Menon R. Intrinsic signal changes accompanying sensory stimulation: functional brain mapping with magnetic resonance imaging. Proc Natl Acad Sci USA 1992; 89(13): 5951-5955.
76. Silvestrini M, Cupini L M, Matteis M, Troisi E, Caltagirone C. Bilateral simultaneous assessment of cerebral flow velocity during mental activity. J Cereb Blood Flow Metab 1994; 14(4): 643-648.
77. Doty R L. Influence of age and age-related diseases on olfactory function. Ann NY Acad Sci 1989; 561: 76-86.
78. Doty R L. Olfactory capacities in aging and Alzheimer's disease: psychophysical and anatomic considerations. Ann NY Acad Sci 1991; 640: 20-27.
79. Doty R L, Perl D P, Steele J C. Olfactory dysfunction in three neurodegenerative diseases. Geriatrics 1991; 46(suppl. 1): 47-51.
80. Serby M, Larson P, Kalkstein D. The nature and course of olfactory deficits in Alzheimer's disease. Am J Psychiatry 1991; 148(3): 357-360.
81. Murphy C, Gilmore M M, Seery C S, Salmon D P, Lasker BR. Olfactory thresholds are associated with degree of dementia in Alzheimer's disease. Neurobiol Aging 1990; 11(4): 465-469.
82. Esiri M M, Wilcock G K. The olfactory bulbs in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1984; 47(1): 56-60.
83. Roberts E. Alzheimer's disease may begin in the nose and may be caused by aluminosilicates. Neurobiol Aging 1986; 7(6): 561-567.
84. Perl D P, Good P F. Uptake of aluminum into central nervous system along nasal-olfactory pathways [letter]. Lancet 1987; i(8540): 1028.
85. Hastings L, Evans J E. Olfactory primary neurons as a route of entry for toxic agents into the CNS. Neurotoxicology 1991; 12(4): 707-714.
86. Reyes P F, Deems D A, Suarez M G. Olfactory-related changes in Alzheimer's disease: a quantitative neuropathologic study. Brain Res Bull 1993; 32(1): 1-5.
87. Tabaton M, Cammarata S, Mancardi G L, Cordone G, Perry G, Loeb C. Abnormal tau-reactive filaments in olfactory mucosa in biopsy specimens of patients with probable Alzheimer's disease. Neurology 1991; 41(3): 391-394.
88. Yamagishi M, Ishizuka Y, Seki K. Pathology of olfactory mucosa in patients with Alzheimer's disease. Ann Otol Rhinol Laryngol 1994; 103(6): 421-427.
89. Zatorre R J, Jones-Gotman M, Evans A C, Meyer E. Functional localization and lateralization of human olfactory cortex. Nature 1992; 360(6402): 339-340.
90. Nasel C, Nasel B, Samec P, Schindler E, Buchbauer G. Functional imaging of effects of fragrances on the human brain after prolonged inhalation. Chem Senses 1994; 19(4): 359-364.
91. Koizuka I, Yano H, Nagahara M. Functional imaging of the human olfactory cortex by magnetic resonance imaging. ORL J Otorhinolaryngol Relat Spec 1994; 56(5): 273-275.
92. Statistical Yearbook 37th issue 1988/89. Department of Economics and Social Development Statistical Office. New York: United Nations, 1992: 544-549.
93. Burt B A. Relative consumption of sucrose and other sugars: has it been a factor in reduced caries experience? Caries Res 1993; 27(suppl. 1): 56-63.
94. Evans D A, Funkenstein H H, Albert M S et al. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. J Am Med Assoc 1989; 262: 2551-2556.
95. Pfeffer R I, Afifi A A, Chance J M. Prevalence of Alzheimer's disease in a retirement community. Am J Epidemiol 1987; 125: 420-436.
96. Rocca W A, Hofman A, Brayne C et al. Frequency and distribution of Alzheimer's disease in Europe: a collaborative study of 1980-1990 prevalence findings. The EURODEM-prevalence research group. Ann Neurol 1991; 30(3): 381-390.
97. US Bureau of the Census, Current Population Reports. 1994: 25-1095.
98. Osuntokun B O, Ogunniyi A O, Lekwauwa G U, Oyediran A B. Epidemiology of age-related dementia in the Third World and aetiological clues of Alzheimer's disease. Trop Geogr Med 1991; 43(4): 345-351.
99. Hendrie H C, Osuntokun B O, Hall K S et al. Prevalence of Alzheimer's disease and dementia in two communities: Nigerian Africans and African Americans. Am J Psychiatry 1995; 152(10): 1485-1492.
100. Razdan S, Kaul R L, Motta A, Kaul S, Bhatt R K. Prevalence and pattern of major neurological disorders in rural Kashmir (India) in 1986. Neuroepidemiology 1994; 13(3): 113-119.
101. Wender M, Mularczyk J, Modestowicz R. Epidemiology of Alzheimer's disease in the selected region of Wielkopolska [town and commune Steszew]. Przegl Epidemiol 1990; 44(3): 215-221.
102. Breteler M M, Claus J J, van Duijn C M, Launer L J, Hofman A. Epidemiology of Alzheimer's disease. Epidemiol Rev 1992; 14: 59-82.
103. Li G, Shen Y C, Chen C H, Zhao Y W, Li S R, Lu M. An epidemiological survey of age-related dementia in an urban area of Beijing. Acta Psychiatr Scand 1989; 79(6): 557-563.
104. Yu E S, Liu W T, Levy P et al. Cognitive impairment among elderly adults in Shanghai, China. J Gerontol 1989; 44(3): S97-S106.
105. Zhang M Y, Katzman R, Salmon D et al. The prevalence of dementia and Alzheimer's disease in Shanghai, China: impact of age, gender, and education. Ann Neurol 1990; 27(4): 428-437.
106. Park J, Ko H J, Park Y N, Jung C H. Dementia among the elderly in a rural Korean community. Br J Psychiatry 1994; 164:796-801.
107. Katzman R, Kawas C. The epidemiology of dementia and Alzheimer's disease. In: Terry R D, Katzman R, Bick K L, eds. Alzheimer Disease. New York: Raven, 1994: 105-122.
108. Oldrige N B. Adherence to adult exercise fitness programs. In: Matarazzo J D, Weiss S M, Herd J A, Miller N E, Weiss S M, eds. Behavioral health: a handbook of health enhancement and disease prevention. New York: Wiley, 1984.
109. Ostrow A C. Physical activity as it relates to the health of the aged. In: Datan N, Lohmann N, eds. Transitions of Aging. New York: Academic Press, 1980.
110. La Rue A, Jarvik L F. Cognitive function and prediction of dementia in old age. Int J Aging Hum Dev 1987; 25: 79-89.
111. Jorm A F. The epidemiology of Alzheimer's disease and related disorders. London: Chapman and Hall, 1990: 148-149.
112. Ohkura T, Isse K, Akazawa K, Hamamoto M, Yaoi Y, Hagino N. Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. Endocr J 1994; 41(4): 361-371.
113. Agnoli A, Fabbrini G, Fioravanti M, Martucci N. CBF and cognitive evaluation of Alzheimer type patients before and after IMAO-B treatment: a pilot study. Eur Neuropsychopharmacol 1992; 2(1): 31-35.
114. Minthon L, Nilsson K, Edvinsson L, Wendt P E, Gustafson L. Long-term effects of tacrine on regional cerebral blood flow changes in Alzheimer's disease. Dementia 1995; 6(5): 245-251.
115. Li W P, Yao Z B, Yang W J, Chen Y C, Peng W H, Hu P. Study of the external counterpulsation (ECP) therapy for senile dementia of the Alzheimer type (SDAT). Chin Med J Engl 1994; 107(10): 755-760.
116. Tuszynski M H, Gage F H. Neurotrophic factors and neuronal loss: potential relevance to Alzheimer disease. In: Terry R D, Katzman R, Bick K L, eds. Alzheimer Disease. New York: Raven, 1994: 405-417.
117. Nordberg A. Clinical studies in Alzheimer patients with positron emission tomography. Behav Brain Res 1993; 57(2): 215-224.
118. Satlin A, Volicer L, Ross V, Herz L, Campbell S. Bright light treatment of behavioral and sleep disturbances in patients with Alzheimer's disease. Am J Psychiatry 1992: 149(8): 1028-1032.
119. Mishima K, Okawa M, Hishikawa Y, Hozumi S, Hori H, Takahashi K. Morning bright light therapy for sleep and behavior disorders in elderly patients with dementia. Acta Psychiatr Scand 1994; 89(1): 1-7.
120. Murphy D G M, Murphy D M, Abbas M et al. Seasonal affective disorder: response to light as measured by electro-encephalogram, melatonin suppression, and cerebral blood flow. Br J Psychiatry 1993; 163: 327-331.
121. Wilson A L, Langley L K, Monley J et al. Nicotine patches in Alzheimer's disease: pilot study on learning, memory, and safety. Pharmacol Biochem Behav 1995; 51(2-3): 509-514.
122. Breitner J C S, Gau B A, Welsh K A et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology 1994; 44: 227-232.
123. Rich J B, Rasmusson D X, Folstein M F, Carson K A, Kawas C, Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 1995; 45: 51-55.
124. Rogers J, Kirby L C, Hempleman S R et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993; 43(8): 1609-1611.
125. Kraaier V, Van Huffelen A C, Wieneke G H, Van der Worp H B, Bar P R. Quantitative EEG changes due to cerebral vasoconstriction: indomethacin versus hyperventilation-induced reduction in cerebral blood flow in normal subjects. Electroencephalogr Clin Neurophysiol 1992; 82(3): 208-212.
126. Jensen K, Freundlich M, Bunemann L, Therkelsen K, Hansen H, Cold G E. The effect of indomethacin upon cerebral blood flow in healthy volunteers: the influence of moderate hypoxia and hypercapnia. Acta Neurocher Wien 1993; 124(2-4): 114-119.
127. Weiner M F, Wighton-Benn W H, Risser R et al. Xenon-133 SPECT-determined regional cerebral blood flow in Alzheimer's' disease: what is typical? J Neuropsychiatry Clin Neurosci 1993; 5(4): 415-418.
128. Soininen H, Helkala E L, Kuikka J. Regional cerebral blood flow measured by 99mTc-HMPAO SPECT differs in sub-groups of Alzheimer's disease. J Neural Transm Park Dis Dement Sect 1995; 9(2-3): 95-109.
129. Duckrow R B. Effect of hemodilution on regional cerebral blood flow during chronic hyperglycemia in rats. Stroke 1990; 21(7): 1072-1076.
130. Rockwood K, Stadnyk K. The prevalence of dementia in the elderly: a review. Can J Psychiatry 1994; 39: 253-257.
131. Sheiham A. Why free sugars consumption should be below 15 kg per person per year in industrialized countries: the dental evidence [see comments]. Br Dent J 1991; 171(2): 63-65.
132. Sparks D L, Hunsaker III J C, Scheff S W, Kryscio R J, Henson J L, Markesbery W R. Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol Aging 1990; 11(6): 601-607.
133. Aronson M K, Ooi W L, Morgenstern H. Women, myocardial infarction, and dementia in the very old. Neurology 1990; 40: 1102-1106.